Testing, Patient Selection, and Individualizing Care for Menin Inhibition in NPM1-Mutated and KMT2A-Rearranged Acute Myeloid Leukemia

Experts explain how menin inhibitors target KMT2A and NPM1 AML, why retesting matters, and how to choose approved drugs or trials.

Experts explain who benefits from menin inhibitors in AML, which tests to order at relapse, and how to choose revumenib vs ziftomenib.

Learn how clinicians recognize and manage drug-related differentiation syndrome, QTc prolongation, and dosing considerations when starting revimumab or ziftomainib in practice.

Explore how menin inhibitors are managed in leukemia care, including key drug interactions, dosing adjustments, and realistic response timelines for patients.

The moderator presents Clinical Scenario 1, the panelists then proceed to discuss how various factors that have been brought up in earlier episodes within this program impact their decisions for the patient in this clinical scenario.

The panelists describe the first 6 weeks for this patient, including twice-weekly labs, weekly EKGs early on, and which checks can be done locally vs at the academic center.

The moderator presents Clinical Scenario 2, a 34-year-old woman with relapsed KMT2A-rearranged AML who has controlled paroxysmal atrial fibrillation, takes posaconazole, and has small children at home.

The panelists discuss how a beta blocker for atrial fibrillation affects baseline cardiac assessment, stressing the QTcF and frequent EKGs when starting revumenib.